Olympus Of Japan Sees China As Ripe For Medical-Gear Equipment
This article was originally published in PharmAsia News
Executive Summary
Japan's Olympus Corp., known for cameras, has plans to expand its medical-equipment business in China and other emerging nations. Olympus has designs to build the Chinese market into its fourth major market, following on its presence in Europe, Japan and the United States. Haruhito Morishima, president of the Olympus Medical Systems subsidiary, which specializes in endoscopes, says the company is attracted by China's huge growth potential. The medical business leads the rest of the parent company in generating profit and already commands 70 percent of the world's endoscope market. (Click here for more - a subscription may be required
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.